Amongst them, a phase I/II clinical trial with a peptidic vaccine composed of E75 (nelipepimut-S, an immunogenic peptide from the HER2 protein) plus GM-CSF for the prevention of disease recurrence in high-risk breast cancer patients demonstrated safety and clinical efficacy in a 5 year follow up [50]. The gene discussed is CSF2; the disease is breast carcinoma.